Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
Despite the introduction of platelet additive solutions for the preparation of pooled platelet components, only a few studies of limited scope have evaluated the clinical efficacy of platelets stored in these solutions. The current report presents an analysis of data to evaluate the response to the transfusion of pooled buffy-coat components suspended in storage solution with reduced (35%) plasma content in comparison with 100% plasma products. During the euroSPRITE clinical trial of platelet components treated with a pathogen inactivation process, control treatment group platelet components were prepared in 100% allogeneic donor plasma (plasma control) or in platelet additive solution (T-Sol) mixed with plasma (T-Sol control). Control group thrombocytopenic patients received either plasma control or T-Sol control platelet components. One-hour and 24-h platelet count increments (CIs) and corrected count increments (CCIs) were analysed for these two types of preparation. In addition, haemostatic assessments were conducted for each transfusion. One-hour and 24-h mean platelet CIs and post-transfusion haemostatic scores were not significantly different for patients receiving platelet components suspended in 100% plasma and T-Sol plasma mixtures. Pooled buffy-coat platelet components prepared in reduced plasma content mixtures provided therapeutic platelet CIs with effective haemostasis.
Sanquin Blood Bank South-west Region, Rotterdam, The Netherlands. dick.van.rhenen@bloodrtd.nl
D J
DJ
van Rhenen
H
H
Gulliksson
J P
JP
Cazenave
D
D
Pamphilon
K
K
Davis
J
J
Flament
L
L
Corash
D016913:Blood Component Transfusion / Q000379:methods*; D001792:Blood Platelets; D004311:Double-Blind Method; D006801:Humans; D007258:Informed Consent; D010949:Plasma; D010976:Platelet Count; D017713:Platelet Transfusion / Q000379:methods*; D012996:Solutions; D013921:Thrombocytopenia / Q000628:therapy*
D012996:Solutions